Clearview Simplify D-dimer is a rapid two-step test for the detection of D-dimer.

Clearly different

Clearview's patented innovative technology provides highly sensitive and specific tests for D-dimer.

• Fast: two easy steps with results in 10 minutes
• Easy: simple test requires no expensive instrumentation or specialized training
• Reliable: built-in control ensures accuracy
• Flexible: faster results while the patient waits

Clearly better

Clearview Simplify D-dimer offers important benefits for you and your patients.

• Aids in the diagnosis of deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC)
• Utilizes the patented 3B6/22 Monoclonal Antibody, specific only for D-dimer, which minimizes the false positives that can be seen with competitive tests
• Reduces the wait for test results
• Can be performed by any staff member, eliminating the need for instrumentation and specialized training

Clearview SIMPLIFY D-dimer Test Procedure

• Whole blood: Use disposable pipette to transfer 1 drop of whole blood (35 µL) to the sample well.
• Plasma: Use a laboratory pipette (not provided) to dispense 20 µL of plasma to the sample well. DO NOT use the disposable pipette.

Apply 2 drops of Clearview Simplify Buffer to the sample well.

Read result in 10 minutes. For full instructions for use, see package insert.

About Thrombosis

A deep vein thrombosis (DVT) is a blood clot that forms in the body's deep veins, usually in the leg or hip veins. In some cases, the clot breaks off, travels through the bloodstream, and obstructs a vessel in the lungs, restricting blood flow. This condition, called pulmonary embolism (PE), can be life-threatening. Venous thromboembolism (VTE; refers to DVT, PE, or a combination of both) affects as many as 2 million people every year in the U.S.¹

During blood coagulation, fibrinogen is converted to fibrin by the activation of thrombin. The resulting fibrin monomers polymerize to form a soluble gel of non-cross-linked fibrin. This fibrin gel is then converted to cross-linked fibrin by thrombin activated Factor XIII to form an insoluble fibrin clot. Production of plasmin, the major clot lysing enzyme, is triggered when a fibrin clot is formed. Although fibrinogen and fibrin are both cleaved by the fibrinolytic enzyme plasmin to yield degradation products, only degradation products from cross-linked fibrin contain D-dimer and are called cross-linked fibrin degradation products.^2-4 Therefore, fibrin derivatives in human blood or plasma containing D-dimer are a specific marker of fibrinolysis.

References

1. Goldhaber SZ, Morrison RB. Cardiology Patient Page: Pulmonary embolism and deep vein thrombosis. Circulation. 2002;106:1436-1438.
2. Gaffney PJ. Distinction between fibrinogen and fibrin degradation products in plasma. Clin Chim Acta. 1978;65(1):109-115.
3. Lane DA, et al. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation. Br J Haematol. 1978;40(4):609-615.
4. Rylatt DB, et al. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res. 1980;18(3-4):453-459.